LONDON (Alliance News) - Akers Biosciences Inc on Wednesday said it has secured a USD2.5 million order from NovoTek Therapeutics Inc.
Under the deal, Akers will supply its PIFA heparin PF4/rapid assay products to NovoTek for distribution in mainland China. The order will be fulfilled in tranches over the course of 2016, with initial sales due to come in the first quarter.
"We look forward to fulfilling this order and to working with NovoTek to build what we believe will be an increasing flow of business for the company over the coming years," said Raymond Akers, co-founder and executive chairman of Akers Biosciences.
Akers shares were untraded on Wednesday, having last traded at 94.55 pence.
By Sam Unsted; samunsted@alliancenews.com; @SamUAtAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.